AJP - Heart BIOPAC complete lab solutions
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 293: H2650-H2658, 2007. First published September 21, 2007; doi:10.1152/ajpheart.00883.2007
0363-6135/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/5/H2650    most recent
00883.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loyer, X.
Right arrow Articles by Samuel, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loyer, X.
Right arrow Articles by Samuel, J.-L.

CALL FOR PAPERS
Cardiovascular-Renal Mechanisms in Health and Disease

Effects of sex differences on constitutive nitric oxide synthase expression and activity in response to pressure overload in rats

Xavier Loyer,1,2 Patricia Oliviero,1,2 Thibaud Damy,1,2,3 Estelle Robidel,1,2 Françoise Marotte,1,2 Christophe Heymes,1,2 and Jane-Lise Samuel1,2

1Institut National de la Santé et de la Recherche Médicale U689, Centre de Recherche Cardiovasculaire Inserm Lariboisière, Paris, France; 2Université Denis Diderot, Paris; and 3Hôpital Lariboisière, Assistance Publique-Hôpital de Paris, Paris, France

Submitted 27 July 2007 ; accepted in final form 18 September 2007


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Clinical studies have documented sex differences in left ventricular (LV) hypertrophy patterns, but the mechanisms are so far poorly defined. This study aimed to determine whether 1) severe pressure overload altered expression and/or activity of cardiac constitutive nitric oxide synthase (NOS1 and NOS3) and 2) these changes were modulated according to sex. Analyses were performed 0.4–20 wk after thoracic aortic constriction (TAC) in male and female Wistar rats. Male rats with TAC exhibited early signs of cardiac dysfunction, as shown by echocardiographic and LV end-diastolic pressure measurements, whereas females with TAC exhibited higher LV hypertrophy (+96% vs. males at 20 wk; P < 0.05). After TAC, cardiac NOS1 expression was rapidly induced (0.4 wk) and stable afterward in males (P < 0.05 vs. sham groups), whereas it was delayed in females. Accordingly, specific NOS1 activity was increased by 2 wk in male rats with TAC (+122%; P < 0.001 vs. sham groups) and only by 20 wk in females (+220%; P < 0.001 vs. sham groups). NOS1 activity was correlated with NOS1 level. Regarding cardiac NOS3, expression was unaffected by TAC, and the decrease in activity observed at early and late times in male and female rats with TAC, respectively, is shown to be related to NOS3 allosteric regulator caveolin-1 level. The data demonstrated a unique sex-dependent regulation of the constitutive NOSs in response to TAC in rats; such a difference might play a role in the sex-dependent adaptability of the heart in response to pressure overload.

caveolae; hypertrophy; heart failure


SEVERAL STUDIES HAVE DOCUMENTED sex differences in the pattern of adaptive left ventricular hypertrophy (LVH) in response to increased afterload, induced by aortic stenosis or hypertension in humans (2, 18) and using experimental models (12, 31). Whether these sex differences result from intrinsic myocardial molecular adaptations to pressure overload is not yet known. One potential mechanism involved in the sex differences is nitric oxide (NO) biodisponiblity (8, 9, 17), which is implicated in the development of LVH and in the transition toward heart failure (HF) (26).1

NO is produced by NO synthases (NOS); the three isoforms are described as follows: two calcium dependent and constitutively expressed [endothelial NOS (or NOS3) and neuronal NOS (or NOS1)] and one calcium independent and inducible (NOS2). All three NOS isoforms may be expressed within the myocardium according to the pathophysiological status (22). In the failing heart, in both humans and rats, myocardial NOS activity is maintained through a distinct regulation of constitutive NOS that includes an increase in NOS1 expression and activity together with a decrease in NOS3 expression and activity (3, 10). One of the major mechanisms regulating the activity of calcium-dependant NOS is through interactions with their allosteric regulators caveolins, the structural proteins of caveolae. Caveolin-1 interacts with NOS3 in endothelium, whereas caveolin-3 interacts with NOS1 in failing cardiomyocytes (10, 22). In isolated and cultured arteries, NOS1 is rapidly induced by increases in intraluminal pressure (13). To get some insight into the mechanisms involved in the cardiac NO production, we investigated the constitutive NOS activity and the regulatory mechanism according to sex differences and pressure overload-induced cardiac hypertrophy. The present study showed that the respective expression of constitutive NOS and caveolins is differentially regulated according to sex in a rat model of pressure overload. The results not only highlight the sex difference of cardiac adaptation to pressure overload, they emphasize the unique mechanisms of NOS activity regulation, that of NOS3 being dependent on caveolin-1 level and NOS1 activity being related to the level of enzyme expression.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals and experimental protocol. The investigation conformed to the National Institutes of Health Guide for Care and Use of Laboratory Animals and was allowed by the Animal Ethics Committee of the Institut National de la Santé et de la Recherche Médicale. The review and approval of our study was obtained by the Local Animal Ethics Committee (no. B 75-10-03).

After anesthesia with intraperitoneal xylazine (50 mg/kg) and ketamine (100 mg/kg), thoracic aortic constriction (TAC) was performed in male (n = 8–10) and female (n = 8–10) 25-day-old Wistar rats (Iffa Credo) by placement of a clip (Atrauclip, Pliling) on the ascending aorta as previously described (1). Additional male (n = 8–10) and female (n = 8–10) age-matched animals underwent sham operation to serve as controls (sham group). Animals were studied by 5 days or 2, 14, or 20 wk after operation. At 2 and 20 wk, echocardiography was performed as described (3).

Echocardiographic, hemodynamic, and anatomic parameters. Transthoracic echocardiography was performed on anesthetized rats with an echocardiograph (Vivid 7, General Electric, Fairfield, CT) equipped with a 10- to 14-MHz linear transducer. Data were transferred online to a computer for blind analysis. The left ventricle (LV) was measured in the parasternal long-axis view in M-mode. LV dimensions were measured during either systole (LVDs) or diastole (LVDd) and used to calculate myocardial performance (% of fractional shortening), calculated as [(LVDd – LVDs)/LVDd] x 100. Each group included 8–10 animals.

Under anesthesia, LV hemodynamic parameters [LV systolic pressure and LV end-diastolic pressure (LVEDP)] were measured before death. Briefly, LV pressure was measured by transparietal route using a needle (n = 8–10 animals per group) and a catheter connected to a pressure transducer. The heart was then removed, dissected, and weighed. Left and right ventricles were separated and weighed, along with the lungs, to determine signs of cardiac hypertrophy and failure. To determine LVH in the animal cohort, we chose to express LVH as the percent increase over LV weight of the respective sham groups (1). Briefly, for each TAC animal, the LVH was calculated according to the formula %LVH = [(TAC LV weight) – (mean LV weight of sham age-matched animals)]/(mean LV weight of sham age-matched animals) x 100, at each time point of the study. The classical heart weight-to-body weight ratio was not considered because of the large variations in body weight over the study in all groups (Table 1), as pointed out by Douglas et al. (12). For the same reason, heart weight normalization to tibia length cannot be used in such long-term studies.


View this table:
[in this window]
[in a new window]

 
Table 1. Anatomic, hemodynamic, and echocardiographic parameters as function of time, sex, and TAC

 
Measurement of NOS activity. NOS activity was measured on whole LV extracts (n = 4 animals per group) by the conversion of L-[3H]arginine (NEN DuPont) to L-[3H]citrulline, using a commercialkit (NOS assay kit, Calbiochem). Assays for specific activity of NOS isoforms were done in the presence of 10–4 M N-nitro-L-arginine methyl ester (Sigma) to inhibit all constitutive isoforms of NOS (NOS1 and NOS3) or 10–5 M vinyl-L-NIO-N5-(1-imino-3-butenyl)-L-ornithine (Alexis), a selective inhibitor of NOS1. NOS3 specific activity was deducted from the difference between total NOS and specific NOS1 activities. Activities are expressed as cpm per 50 µg per 30 min.

Protein extractions. LV fragments (20–30 mg) were lysed with an Ultraturax (Polytron) in Triton X-100 buffer for NOS expression [1% Triton X-100, 50 mM Tris·HCl, pH 7.4, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM beta-glycerophosphate, 0.2 mM sodium orthovanadate, and Complete protease inhibitor cocktail (Roche)] and stored on ice for 1 h. After centrifugation at 12,000 rpm for 10 min at 4°C, supernatants, corresponding to the Triton X-100 soluble fraction, were stored at –20°C. For caveolin analysis (caveolin-1 and caveolin-3), proteins were solubilized in SDS buffer [1% SDS, 10 mM Tris·HCl, pH 7.4, 1 mM orthovanadate-sodium, and Complete protease inhibitor cocktail (Roche)]. Lysates were warmed for 15 s in a microwave (900 W) and centrifuged at 12,000 rpm at 15°C for 5 min. Supernatants obtained were stored at –20°C.

To analyze protein-protein interactions, an N-octylglucoside (OG; Roche) lysis buffer was employed. Briefly, LV fragments were lysed with an Ultraturax (Polytron) in OG buffer [600 mM OG, 10 mM Tris·HCl, pH 8, 150 mM NaCl, 10 mM NaF, 1 mM orthovanadate, Complete protease inhibitor cocktail (Roche)]. After centrifugation (12,000 rpm, 5 min, 15°C), supernatants were collected. Protein concentrations were measured by bicinchoninic acid protein assay (Pierce) by comparison with a BSA standard curve.

Western blotting. Proteins samples (n = 8–10 per group) were separated by electrophoresis on 12% and 7.5% SDS-PAGE gels (for caveolin-1 and -3 and for NOS3 and NOS1, respectively) and transferred to nitrocellulose (Schleicher & Schuell) membranes in 25 mM Tris, 192 mM glycine, 0.01% SDS, and 15% ethanol. The equal loading was verified by Ponceau S red (Sigma) staining (data not shown) and by probing the immunoblot samples with MAb against GAPDH (1:5,000; Chemicon). The membranes were blocked with a Tris-buffered saline (pH 7.4) with 0.1% Tween 20 (Sigma) and 5% nonfat dry milk for 1 h at room temperature before incubation with each antibody: anti-caveolin MAb (1:8,000; Transduction Lab), anti-caveolin-3 MAb (1:2,000; Transduction Lab), anti-NOS3 polyclonal Ab (1:1,000; Santa Cruz), and anti-NOS1 polyclonal Ab (1:1,000; Affinity Bioreagent). After they were washed, membranes were incubated for 1 h at room temperature with an anti-mouse IgG or an anti-rabbit IgG conjugated to horseradish peroxidase (1:5,000; Amersham). After samples were washed, bands were revealed by chemiluminescence using ECL+ (Amersham) and quantified by using a computer system (Image Gauge) and normalized to actin (Ponceau S red) and GAPDH.

Coimmunoprecipitation assays. For coimmunoprecipitation, OG lysate proteins (300 µg) were incubated overnight at 4°C with different antibodies according to the protein complex studied. To investigate NOS3-caveolin-1 interactions, OG lysates were incubated overnight at 4°C with caveolin-1 MAb at a final concentration of 5 µg/ml in 400 µl of immunoprecipitation buffer (1% Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 10 mM Tris·HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, and protease inhibitor cocktail). Anti-mouse IgG-conjugated agarose (Sigma) was added at 4°C for 3 h. After centrifugation, the supernatant was stored, and aliquots (10 µl) were used for Western blotting. The pellets were washed in immunoprecipitation buffer, and the immunoprecipitates were eluted in Laemmli buffer and separated in two parts for Western blot analysis. Coimmunoprecipitation and supernatant samples were analyzed by electrophoresis and immunoblotted with NOS3 polyclonal Ab (1:1,000). For coimmunoprecipitation between NOS1 and caveolin-3, OG lysates were incubated overnight with anti-NOS1 polyclonal Ab (5 µg/ml in 400 µl of immunoprecipitation buffer). Protein A sepharose (Amersham) was added at 4°C for 3 h. After centrifugation, the protocol was similar to that described above, and membranes were incubated with caveolin-3 MAb (1:1,000). To investigate NOS3-caveolin-3 interactions, OG lysates were incubated overnight with caveolin-3 MAb (5 µg/ml in 400 µl of immunoprecipitation buffer). Anti-mouse IgG-conjugated agarose (Sigma) was added at 4°C for 3 h. After centrifugation, the fractions were processed as described above. The membranes were immunoblotted with NOS3 polyclonal Ab (1:1,000). Of note, to verify that the amount of supernatant protein loaded did not vary, the membranes were probed with GAPDH (1:5,000; Chemicon).

Statistical analysis. Data are expressed as means ± SE. Statistical analysis was performed with Statview. ANOVA followed by a Bonferroni-Dunn correction was performed. P < 0.05 after Bonferroni correction is considered significant. For comparison between two groups, Student's t-test was used.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Time course analysis of anatomic and hemodynamic parameters according to sex difference and cardiac status. TAC induced similar increases in LV systolic pressure in male and female rats, indicating that the severity of constriction was comparable (Table 1). As shown in Table 1, at the early time after TAC (i.e., 5 and 15 days), the LVEDP was either normal or very slightly increased in female groups, whereas it was significantly increased in male groups by 2 wk (+37%; P < 0.05 vs. male sham rats). In contrast, by 14 and 20 wk, further increases in LVEDP were observed in male TAC compared with female TAC animals (+60%; P < 0.05 vs. female TAC rats at the same time point), indicating a LV dysfunction in males.

Echocardiographic analysis, performed at 2 and 20 wk, also indicated that males exhibited earlier signs of cardiac dysfunction in response to TAC than females (Fig. 1). By 2 wk after TAC, percent fractional shortening was decreased in males (–50%; P < 0.05 vs. male sham group) and did not vary afterward. In contrast, females exhibited moderate signs of cardiac dysfunction only by 20 wk after TAC (Fig. 1A; %fractional shortening: –30%; P < 0.05 vs. results for female TAC). Further echocardiography parameter analysis revealed that more pronounced percent fractional shortening alterations in males were mainly due to the increase of LV cavity size during systole without any changes in LV cavity size during diastole (Table 1).


Figure 1
View larger version (15K):
[in this window]
[in a new window]

 
Fig. 1. Fractional shortening (FS) and left ventricular hypertrophy (LVH) as a function of sex and cardiac status. A: percentage of FS (FS%) by 2 and 20 wk. Open columns = sham groups and solid columns = thoracic aortic constriction (TAC) groups; nos. under columns show no. of animals/group. *P < 0.05 vs. respective sham animals; {dagger}P < 0.05 vs. male TAC (M-TAC) group. B: LVH is expressed as percentage of respective sham animals at each time point of the study. bullet, female TAC (F-TAC) group; {blacktriangleup}, male (M) TAC group. In males, n = 8 at 5 days and n = 9 at 2, 14, and 20 wk. In females, n = 10 at 5 days and n = 8 at 2 wk, 10 by 14 wk, and 9 by 20 wk. *P < 0.05 vs. F-TAC at the same time point.

 
As shown in Fig. 1B, LVH in response to TAC was observed as early as 5 days after surgery in both male and female rats (P < 0.05 vs. respective sham animals). Of note, by 5 days, LVH was markedly greater in male than in female rats (+58%; P < 0.05 vs. females with TAC). At day 5, the degree of cardiac hypertrophy was similar for any of the indexes used (LV/body wt or LV/tibia length). Afterward, LVH in males was established and did not change until 20 wk. In females, LVH continuously increased with time and became higher than in male rats after 14 wk (Fig. 1B; P < 0.05 vs. male TAC at both 14 and 20 wk). The anatomic analysis revealed a higher increase in RV weight in male than in female rats from 2 to 20 wk after TAC (P < 0.05 vs. female TAC) (Table 1). Lung weight significantly increased in response to TAC at 14 and 20 wk, indicating HF signs in both sexes (Table 1). Hence, in response to TAC, males exhibited signs of cardiac dysfunction before female animals.

Cardiac NOS activities according to sex difference and LVH status. We choose 2 and 20 wk as early and late time points, respectively, to study total and specific NOS activities in the LV extracts (Fig. 2).


Figure 2
View larger version (18K):
[in this window]
[in a new window]

 
Fig. 2. Cardiac nitric oxide synthase (NOS) activities in response to TAC according to sex at 2 and 20 wk after imposition of TAC. Open bars = sham groups; solid bars = TAC groups. A: total cardiac activity of constitutive NOS; n = 4/group. {dagger}P < 0.05 vs. males whatever the group. B: specific NOS1 activity. *P < 0.05 vs. respective sham groups; {ddagger}P < 0.05 vs. M-TAC. C: specific NOS3 activity. *P < 0.05 vs. respective sham groups. cpm, Counts per minute.

 
By 2 wk after surgery, the total NOS activity in the female hearts was higher than shown in males without any influence of TAC (P < 0.05 vs. male rats). Afterward, no difference was found between the experimental groups (Fig. 2A).

As shown in the Fig. 2B, the cardiac-specific NOS1 activity of sham animals was relatively low and stable for both male and female rats. By 2 and 20 wk after TAC, the cardiac NOS1 activity markedly increased in males (+122%; P < 0.05 vs. male sham group). In contrast, in females, the cardiac NOS1 activity increased only at the late point (+313%; P < 0.05 vs. female sham group), being at that time significantly higher than in males with TAC.

As shown in Fig. 2C, the specific NOS3 activity was similar in the sham groups. By 2 wk after TAC in males, NOS3 activity dramatically decreased (–54%; P < 0.05 vs. male sham group) and remained stable afterward. It is worth noting that, in female rats, NOS3 activity declined only by 20 wk after TAC (–74%; P < 0.05 vs. respective sham).

These results indicate that 1) total cardiac NOS activity is stable whatever the cardiac status and sex and 2) after TAC, specific changes in NOS3 and NOS1 activities occurred earlier in males than in females.

NOS3 and NOS1 expression in the heart according to sex and hypertrophic status. Figure 3, A and C, shows that in all sham animals NOS1 expression was stable, as previously reported (14). After TAC was performed, cardiac NOS1 expression increased as early as after 5 days and reached a plateau in male rats (+65%; P < 0.05 vs. male sham animals). In contrast, in females with TAC, NOS1 level was moderately enhanced by 2 wk (+15%) and further increased at the late time points (+70%; P < 0.05 vs. female sham group).


Figure 3
View larger version (22K):
[in this window]
[in a new window]

 
Fig. 3. Cardiac NOS1 and NOS3 expressions as a function of sex, TAC, and time after surgery. A and B: representative NOS1 (50 µg protein/lane) and NOS3 (15 µg protein/lane) Western blots performed with left ventricular (LV) extracts. All immunoblots were probed with GAPDH. C and D: respective quantification of NOS1 and NOS3 in the experimental groups. AU, arbitrary unit. Numbers of samples are as follows: 9 M-sham (Sh) and 8 M-TAC at 5 days; 8 M-sham and 9 M-TAC at 2 wk; 8 M-sham and 9 M-TAC at 14 wk; and 8 M-sham and 9 M-TAC at 20 wk. In female groups, numbers of samples are as follows: 10 F-sham and 10 F-TAC at 5 days; 9 F-sham and 8 F-TAC 2 wk; 9 F-sham and 10 F-TAC at 14 wk; and 8 F-sham and 9 F-TAC at 20 wk. {triangleup}, M-sham; {blacktriangleup}, M-TAC; {circ}, F-sham; bullet, F-TAC. *P < 0.05 vs. males whatever the cardiac status; {dagger}P < 0.05 vs. F-sham; {ddagger}P < 0.05 vs. M-sham; $P < 0.05 vs. sham groups.

 
As shown in Fig. 3, B and D, NOS3 protein expression in male hearts did not vary according to time or cardiac status. In female rats at the earliest time of the study (5 days and 2 wk), NOS3 expression was 1) higher than in males (+50%; P < 0.05 vs. males) and 2) unaltered by TAC. Later on, despite a downregulation, NOS3 expression remained higher in the female TAC groups (>30%; P < 0.05 vs. female sham animals).

Cardiac expression of caveolins-1 and -3 according to sex and hypertrophic status. As shown in Fig. 4, A and C, TAC induced a decrease in caveolin-1 expression in male hearts by day 5 (–35%; P < 0.05 vs. respective shams), whereas in females caveolin-1 level fell only at 20 wk (–65%; P < 0.05). In all sham animals, caveolin-1 expression was stable.


Figure 4
View larger version (23K):
[in this window]
[in a new window]

 
Fig. 4. Cardiac caveolin-1 and caveolin-3 expressions after TAC according to sex. A and B: representative caveolin-1 and caveolin 3 Western blots performed with LV extracts. All immunoblots were probed with GAPDH. C and D: quantification of caveolin-1 and -3 at different times. Numbers of samples in male groups are as follows: 9 M-sham and 8 M-TAC at 5 days; 8 M-sham and 9 M-TAC at 2 wk; 8 M-sham and 9 M-TAC at 14 wk; and 8 M-sham and 9 M-TAC at 20 wk. Numbers of samples in female groups are as follows: 10 F-sham and 10 F-TAC at 5 days; 9 F-sham and 8 F-TAC at 2 wk; 9 F-sham and 10 F-TAC at 14 wk; and 8 F-sham and 9 F-TAC at 20 wk. {triangleup}, M-sham; {blacktriangleup}, M-TAC; {circ}, F-sham; bullet, F-TAC. *P < 0.05 vs. M-sham; {dagger}P < 0.05 vs. F-sham at time considered; {ddagger}P < 0.05 vs. males.

 
As indicated in Fig. 4, B and D, caveolin-3 levels were transiently higher in females than in males at the earliest time point (P < 0.05 vs. females) without any significant effect of TAC.

Interactions between caveolin and NOS isoforms. The relative levels of interactions between NOS3 and caveolin-1, on one hand, and between NOS1 and caveolin-3, on the other hand, were investigated by coimmunoprecipitation by 2 and 20 wk (Fig. 5, A and B). The relative amount of NOS3 bound to caveolin-1 complexes remained stable whatever the experimental conditions (Fig. 5A). In contrast, the relative amount of NOS1-caveolin-3 complexes was two- to fourfold higher in females than in males (Fig. 5B; P < 0.05 vs. male rats). In response to TAC, NOS1-caveolin-3 complexes significantly increased by wk 2 in male groups only (P < 0.05 vs. male sham group). This difference did not exist by 20 wk.


Figure 5
View larger version (15K):
[in this window]
[in a new window]

 
Fig. 5. Caveolin-NOS interactions as function of sex and TAC 2 and 20 wk after surgery. A: representative immunoblots of NOS3 unbound and bound to caveolin-1 (Cav-1) as function of sex and cardiac status by 2 and 20 wk after TAC and corresponding quantification of the relative amount of NOS3 bound to Cav-1; n = 4 animals/group. Supernatants were probed by GAPDH immunoblots to verify that the amount of protein loaded was similar. B: representative immunoblots of caveolin-3 (Cav-3) unbound and bound to NOS1 as function of sex and cardiac status by 2 and 20 wk post-TAC and corresponding quantification of the relative amount of Cav-3 bound to NOS1; n = 4 animals/group. Supernatants were probed by GAPDH immunoblots to verify that the load was similar. *P < 0.05 vs. males; {dagger}P < 0.05 vs. M-sham. C: representative immunoblots of NOS3 unbound and bound to Cav-3 as function of sex and cardiac status by 2 and 20 wk after TAC; n = 4 animals/group. Supernatants were probed by GAPDH immunoblots to verify that the amount of protein loaded was similar.

 
Regarding NOS3 caveolin-3 interactions (Fig. 5C), we did not find evidence of any changes in NOS3-caveolin-3 interactions as a function of sex, time, and TAC. In the supernatant fraction (10 µl over 400 µl), differences in NOS3 expression according to age in females were observed. The quantification of NOS3 bound to caveolin-3 was at <5% of total NOS3 as described in Bendall et al. (3) (data not shown).

Regulation of specific NOS activities. Correlation analysis allowed us to exclude any relationship between the specific NOS activities and their respective levels of interactions with caveolins (NOS3-caveolin-1 or NOS1-caveolin-3; data not shown). In contrast, we found that NOS3 activity was related to caveolin-1 level (R2 = 0.81) (Fig. 6A), whereas NOS1 activity was correlated to the NOS1 level (R2 = 0.82) (Fig. 6B). These correlations emphasized the distinct mechanisms involved in the control of NOS activity in the heart.


Figure 6
View larger version (10K):
[in this window]
[in a new window]

 
Fig. 6. Factors able to modulate NOS3 and NOS1 activity in rat hearts. {triangleup}, M-sham; {blacktriangleup}, M-TAC; {circ}, F-sham; bullet, F-TAC. A: LV NOS3 activity is closely related to caveolin-1 expression when different groups are considered (R2 = 0.81). B: LV NOS1 activity is related to NOS1 protein expression (R2 = 0.82).

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This study is the first to demonstrate that the pattern of NOS expression and/or activity is specifically regulated according to sex and cardiac functional status.

The present data confirm that females, in response to pressure overload, have a greater hypertrophic reserve than males (12, 29). The delay in the occurrence of maladaptive hypertrophy, observed herein with female rats, could be due to estrogen effects as previously proposed in both rats and humans (24). To further explore the sex differences in the susceptibility to develop HF, we analyzed the NOS activities and the expression of the two constitutive NOS isoforms together with their major allosteric regulators.

An increase in NOS1 activity and expression has been demonstrated in experimental and human HF (3, 10), in aged hypertensive rats (23), and soon after ANG II infusion (28). Herein, we provide the first evidence that the upregulation of NOS1 in the heart is a primary response to pressure overload. Indeed in male rats, NOS1 expression is a very early (5 days) and sustained response to TAC. In female rats, the onset of NOS1 induction is delayed (≥2 wk), but NOS1 expression rises with time. The TAC-induced increase in wall stress occurs earlier in males than in females (12). Therefore, we might hypothesize that increase in wall stress is a major trigger of NOS1 expression. Furthermore, in females, the further development of cardiac hypertrophy tends to decrease the wall stress, and when the limits of adaptive hypertrophy are reached, NOS1 is induced. Further investigations are needed to verify this hypothesis. It is worthy to note that NOS1 activity is tightly related to the enzyme level of expression (Fig. 5B). In line with this concept, NOS1 expression and activity have been shown to increase in response to mechanical loading in skeletal muscle (30, 32). As a result, in both cardiac and skeletal muscles, the mechanosensitive pathway triggers NOS1 expression and activity.

Conversely to ischemia-reperfusion or HF situations during which NOS1 is translocated to caveolae through interactions with caveolin-3 (3, 10, 27), pressure overload did not alter significantly the subcellular distribution of NOS1 in the rat heart (Fig. 5). These data raise the question of the role of NOS1 in the heart following TAC. It has been proposed that NOS1 could be beneficial for cardiac function in HF secondary to myocardial infarction (3, 11, 25). Here, we demonstrated that the NOS1 induction preceded but did not prevent the occurrence of cardiac dysfunction. Therefore, it is tempting to speculate that the stretch-induced NOS1 contributes to the ultimate phase of myocyte hypertrophy (5, 20) when the process became maladaptive (15).

Regarding NOS3, with the exception of age-dependent changes in females, the protein expression was remarkably stable whatever the cardiac status, as observed in males (21). The regulation of caveolin-1, the major partner of NOS3, differed. Indeed, the caveolin-1 levels were downregulated in response to TAC, the temporal pattern of expression being sex specific, that is, early and sustained in males and delayed in females. The fact that NOS3 activity was closely related to caveolin-1 expression (Fig. 6A) emphasizes not only the enzyme location at the level of endothelial caveolae but the importance of caveolin-1 in the NOS3-derived NO production in heart. It is worthy to note that NOS3-caveolin-3 interactions are minute (i.e., <5% of NOS3) and unmodified by age, sex, or hypertrophy status. This result points out the modest NOS3 distribution in muscle cells.

It therefore appears that the occurrence of endothelial dysfunction associated with the decreased NOS3 activity is sex difference dependent, highlighting the estrogen protection of the endothelium through the control of caveolin expression (16, 24) in the heart in response to a pathological situation.

Limitations of the study. It should be stressed that study of animals of different ages and body size changes is complex. Accordingly, we chose to normalize data to same-sex control values (LVH: the ratio between TAC LV weight to sham LV weight mean), as proposed by Douglas et al. (12). Indeed, as outlined by these authors, in long-term study, neither LV weight-to-body weight ratio nor LV weight-to-tibia length ratio can be used to normalize hypertrophy process because of the limitations of growth, age, and sex.

Another change related to development observed in the study was the differences in NOS activity with time in sham female animals compared with sham males. The data relative to age-related variations of NOS activity according or not to sex differences are rather few. There are reports on aging and on neonatal development (4), which have indicated a decrease in NOS3 activity from birth to adult and or senescent stages. In addition, Esberg et al. (14) observed that young female rats have higher NOS activities than males. Furthermore, we have demonstrated that estrogen stimulates NOS3 activity (19). Therefore, considering that, at 2 wk after surgery, rats were 40 days old, an age close to sexual maturity in females, we might propose that estradiols play a role in the higher NOS3 expression and activity observed in juvenile females vs. that shown in with age-matched male or older female animals. Such age-related variations in NOS3 activity in female animals must be considered in future studies.

The respective functions of NOS1 and NOS3 and of NOS1/3-derived NO were not addressed in the present study. It has been suggested that NOS3-derived NO, or exogenous NO, may be involved in preventing the development of cardiac hypertrophy (6). The present data indicate that the early decrease in NOS3-derived NO in male rats was not sufficient to allow the development of cardiac hypertrophy with time comparatively to female rats. Rather, such a drop in NOS3 activity underlined the endothelial dysfunction in male, which in turn participates in the development of HF (26). In females, through the beneficial effect of estrogens (24), the long lasting maintenance of endothelial function likely prevents the occurrence of HF. With regard to NOS1, it has been proposed that the enzyme modulates calcium homeostasis and beta-adrenergic response (7). Our results demonstrating active NOS1 in all hypertrophic myocardium are in line with a protrophic role of NOS1, as recently proposed (5, 20). Furthermore, NOS1-caveolin-3 complexes in females could protect cardiomyocytes, as proposed by Sun et al. (27).

To conclude, it emerged that, although total NOS activity in the heart remained unchanged against severe pressure overload, specific changes in NO compartmentation due to NOS1 or NOS3, respectively, might be involved in the development of cardiac hypertrophy and failure. Finally, the study emphasized the specific regulation of constitutive NOS isoform activities according to sex and the pathophysiological situation in the heart by two distinct pathways, the activity of NOS1 depending on transcriptional mechanism and that of NOS3 controlled through allosteric regulators.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The work was supported by Institut National de la Santé et de la Recherche Médicale, Institut National de la Santé et de la Recherche Médicale grants for "Programme National de Recherche sur les Maladies Cardiovasculaires," and Fondation de France. X. Loyer has a fellowship from Ministère de la Recherche et de l'Enseignement Supérieur and Société Française d'Hypertension Artérielle.


    ACKNOWLEDGMENTS
 
We thank Dr. C. Delcayre and Dr. B. Swynghedauw for helpful discussions.


    FOOTNOTES
 

Address for reprint requests and other correspondence: J.-L. Samuel, CRCIL INSERM U689, 41, Bd de la Chapelle 75475 Paris cedex 10, France (e-mail: samuel{at}larib.inserm.fr)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This paper was presented at the 9th Cardiovascular-Kidney Interactions in Health and Disease Meeting at Amelia Island Plantation, Florida, on May 26–29, 2006. Back


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Anger M, Lompre AM, Vallot O, Marotte F, Rappaport L, Samuel JL. Cellular distribution of Ca2+ pumps and Ca2+ release channels in rat cardiac hypertrophy induced by aortic stenosis. Circulation 98: 2477–2486, 1998.[Abstract/Free Full Text]
  2. Aurigemma GP, Gaasch WH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 86: 310–317, 1995.[Web of Science][Medline]
  3. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I, Milliez P, Robidel E, Marotte F, Samuel JL, Heymes C. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110: 2368–2375, 2004.[Abstract/Free Full Text]
  4. Bloch W, Fleischmann BK, Lorke DE, Andressen C, Hops B, Hescheler J, Addicks K. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res 43: 675–684, 1999.[Abstract/Free Full Text]
  5. Burkard N, Rokita AG, Kaufmann SG, Hallhuber M, Wu R, Hu K, Hofmann U, Bonz A, Frantz S, Cartwright EJ, Neyses L, Maier LS, Maier SK, Renne T, Schuh K, Ritter O. Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res 100: e32–e44, 2007.[Abstract/Free Full Text]
  6. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101: 812–818, 1998.[Web of Science][Medline]
  7. Casadei B. The emerging role of neuronal nitric oxide synthase in the regulation of myocardial function. Exp Physiol 91: 943–955, 2006.[Abstract/Free Full Text]
  8. Chen J, Petranka J, Yamamura K, London RE, Steenbergen C, Murphy E. Gender differences in sarcoplasmic reticulum calcium loading after isoproterenol. Am J Physiol Heart Circ Physiol 285: H2657–H2662, 2003.[Abstract/Free Full Text]
  9. Cross HR, Murphy E, Koch WJ, Steenbergen C. Male and female mice overexpressing the beta2-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide. Cardiovasc Res 53: 662–671, 2002.[Abstract/Free Full Text]
  10. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G, Marotte F, Samuel JL, Heymes C. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363: 1365–1367, 2004.[CrossRef][Web of Science][Medline]
  11. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 112: 3729–3737, 2005.[Abstract/Free Full Text]
  12. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 32: 1118–1125, 1998.[Abstract/Free Full Text]
  13. Ebrahimian T, Mathieu E, Silvestre JS, Boulanger CM. Intraluminal pressure increases vascular neuronal nitric oxide synthase expression. J Hypertens 21: 937–942, 2003.[CrossRef][Web of Science][Medline]
  14. Esberg LB, Zhang X, Scott GI, Culver B, Ren J. Impact of gender on basal and insulin-like growth factor I-regulated nitric oxide synthase activity in adult rat left ventricular myocytes. Comp Biochem Physiol A 138: 141–146, 2004.[CrossRef][Medline]
  15. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580–1589, 2004.[Abstract/Free Full Text]
  16. Jayachandran M, Hayashi T, Sumi D, Iguchi A, Miller VM. Temporal effects of 17beta-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 281: H1327–H1333, 2001.[Abstract/Free Full Text]
  17. Knot HJ, Lounsbury KM, Brayden JE, Nelson MT. Gender differences in coronary artery diameter reflect changes in both endothelial Ca2+ and ecNOS activity. Am J Physiol Heart Circ Physiol 276: H961–H969, 1999.[Abstract/Free Full Text]
  18. Liao Y, Cooper RS, Mensah GA, McGee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 92: 805–810, 1995.[Abstract/Free Full Text]
  19. Loyer X, Damy T, Chvojkova Z, Robidel E, Marotte F, Oliviero P, Heymes C, Samuel JL. 17beta Estradiol regulates constitutive nitric oxide synthase expression differentially in the myocardium in response to pressure overload. Endocrinology 148: 4579–4584, 2007.[Abstract/Free Full Text]
  20. Loyer X, Vinet L, Wang Y, Milliez P, Robidel E, Jaisser F, Samuel JL, Heymes C. Role of myocardial neuronal nitric oxide synthase in the development of cardiac hypertrophy. J Mol Cell Cardiol 40: 950, 2006.
  21. MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ, Shah AM. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104: 2967–2974, 2001.[Abstract/Free Full Text]
  22. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93: 388–398, 2003.[Abstract/Free Full Text]
  23. Piech A, Dessy C, Havaux X, Feron O, Balligand JL. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res 57: 456–467, 2003.[Abstract/Free Full Text]
  24. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5: 425–438, 2006.[CrossRef][Web of Science][Medline]
  25. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, Vandegaer K, Li D, Hare JM. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 112: 3415–3422, 2005.[Abstract/Free Full Text]
  26. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86: 49–86, 2000.[CrossRef][Web of Science][Medline]
  27. Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C, Murphy E. Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel {alpha}1 subunit and reduced ischemia/reperfusion injury. Circ Res 98: 403–411, 2006.[Abstract/Free Full Text]
  28. Tambascia RC, Fonseca PM, Corat PD, Moreno H Jr, Saad MJ, Franchini KG. Expression and distribution of NOS1 and NOS3 in the myocardium of angiotensin II-infused rats. Hypertension 37: 1423–1428, 2001.[Abstract/Free Full Text]
  29. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 33: 676–680, 1999.[Abstract/Free Full Text]
  30. Tidball JG, Lavergne E, Lau KS, Spencer MJ, Stull JT, Wehling M. Mechanical loading regulates NOS expression and activity in developing and adult skeletal muscle. Am J Physiol Cell Physiol 275: C260–C266, 1998.[Abstract/Free Full Text]
  31. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, Douglas PS, Lorell BH. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 34: 264–273, 1999.[Abstract/Free Full Text]
  32. Zhang JS, Kraus WE, Truskey GA. Stretch-induced nitric oxide modulates mechanical properties of skeletal muscle cells. Am J Physiol Cell Physiol 287: C292–C299, 2004.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
X. Loyer, A. M. Gomez, P. Milliez, M. Fernandez-Velasco, P. Vangheluwe, L. Vinet, D. Charue, E. Vaudin, W. Zhang, Y. Sainte-Marie, et al.
Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling
Circulation, June 24, 2008; 117(25): 3187 - 3198.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. C. Gillebert and N. R. Van de Veire
About left ventricular torsion, sex differences, shear strain, and diastolic heart failure
Eur. Heart J., May 2, 2008; 29(10): 1215 - 1217.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/5/H2650    most recent
00883.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loyer, X.
Right arrow Articles by Samuel, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loyer, X.
Right arrow Articles by Samuel, J.-L.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.